R&D Pipeline
R&D Pipeline (In-House)
As of July 2025
| Generic name / Development code |
Expected indications | Category | Development stage | Development classification |
|
Linzagolix |
Uterine fibroids | GnRH receptor antagonist | NDA | Kissei |
| Endometriosis | Phase III |
Kissei | ||
| Cretostimogene grenadenorepvec / CG0070 |
Non-muscle-invasive bladder cancer in high-risk patients | Oncolytic Viral Therapy | Phase III | In-licensed / CG Oncology (U.S.) |
| Rovatirelin / KPS-0373 |
Spinocerebellar degeneration | TRH receptor agonist | Phase III |
In-licensed / Shionogi (Japan) |
| Matsupexole / KDT-3594 |
Parkinson's disease | Dopamine receptor agonist | Phase II | Kissei |
| Olutasidenib | Relapsed/refractory acute myeloid leukemia | IDH1 inhibition | Clinical trial preparation | In-licensed / Rigel (U.S.) |
R&D Pipeline (Out-Licensing)
As of July 2025
| Generic name | Expected indications | Category | Countries ＆ Regions | Development company | Development stage |
| Linzagolix | Uterine fibroids | GnRH receptor antagonist | 4 countries*1 | Theramex (U.K.) | NDA |
| Taiwan | Synmosa Biopharma (Taiwan) | NDA | |||
| Endometriosis | 3 countries*2 | Theramex (U.K.) | NDA | ||
| Silodosin | Dysuria associated with benign prostatic hyperplasia | Alpha 1A adrenergic receptor antagonist | Vietnam, etc. | Eisai (Japan) | NDA |
*1 Switzerland, Brazil, Republic of South Africa and Mexico
*2 Brazil, Republic of South Africa and Mexico
